No Data
Subdued Growth No Barrier To ApicHope Pharmaceutical Group Co., Ltd. (SZSE:300723) With Shares Advancing 30%
ApicHope Pharmaceutical (300723.SZ) plans to launch an incentive plan for no more than 7.652 million Stocks Options.
ApicHope Pharmaceutical (300723.SZ) disclosed the draft of the 2025 Stocks Options incentive plan, this incentive plan...
Private Companies Are ApicHope Pharmaceutical Group Co., Ltd.'s (SZSE:300723) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥467m Last Week
Poinsettia: 2024 performance forecast
Involved in the "first major bidding case of national procurement", ApicHope Pharmaceutical may face its first loss after going public | Interpretations
① Due to the continued increase in research and development investment, reimbursement of medical insurance refunds, and other factors, ApicHope Pharmaceutical may experience its first loss since its listing in 2024. ② It is expected that the net loss in Q4 will be between 0.225 billion yuan and 0.433 billion yuan.
ApicHope Pharmaceutical (300723.SZ) announces a预亏, expecting a net loss of 0.472 billion yuan to 0.68 billion yuan for the fiscal year 2024, turning from profit to loss.
ApicHope Pharmaceutical (300723.SZ) released its performance forecast for 2024, predicting that the annual net profit attributable to shareholders will be...
Do ApicHope Pharmaceutical's (SZSE:300723) Earnings Warrant Your Attention?
